Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma

Blood Advances
Tomer M MarkRuben Niesvizky

Abstract

The addition of clarithromycin enhances the efficacy of lenalidomide plus dexamethasone in treatment-naive multiple myeloma (MM). We conducted a phase 2 trial to evaluate the safety and efficacy of clarithromycin, pomalidomide, and dexamethasone (ClaPd) in relapsed or refractory multiple myeloma (RRMM) with prior lenalidomide exposure. One hundred twenty patients with a median of 5 prior lines of therapy received clarithromycin 500 mg orally twice daily, pomalidomide 4 mg orally on days 1 to 21, and dexamethasone 40 mg orally on days 1, 8, 15, and 22 of a 28-day cycle. The overall response rate (ORR) was 60% with 23% achieving at least a very good partial response. There was no statistical difference in response rates for patients who were refractory to lenalidomide (ORR, 58%), bortezomib (ORR, 55%), or both lenalidomide and bortezomib (ORR, 54%). Median progression-free survival (PFS) for the cohort was 7.7 months and median overall survival (OS) was 19.2 months. A history of dual-refractoriness to lenalidomide and bortezomib did not significantly impact either PFS or OS. The most common toxicities were neutropenia (83%), lymphopenia (74%), and thrombocytopenia (71%). The most common grade ≥3 toxicities included neutropenia (5...Continue Reading

References

Apr 30, 1999·International Journal of Antimicrobial Agents·A A KhanJ S Remington
Jun 9, 1999·The Journal of Allergy and Clinical Immunology·D A FostJ D Spahn
Dec 12, 2001·Seminars in Oncology·T HideshimaK C Anderson
Mar 12, 2004·International Journal of Antimicrobial Agents·Gigliola ReatoNicola A Carlone
Oct 3, 2009·Leukemia·R FonsecaUNKNOWN International Myeloma Working Group
Sep 3, 2010·International Journal of Oncology·Miki NakamuraHiroyuki Hata
Feb 5, 2011·Blood·S Vincent RajkumarUNKNOWN International Myeloma Workshop Consensus Panel 1
Apr 11, 2013·Drugs·Shelley Elkinson, Paul L McCormack
Oct 28, 2015·Acta Haematologica·Xu-Hua QiuHong-Qin Cao
Nov 8, 2018·The New England Journal of Medicine·Meletios A DimopoulosJesús San-Miguel

❮ Previous
Next ❯

Citations

Nov 5, 2019·Expert Review of Anticancer Therapy·Evangelos Eleutherakis-PapaiakovouMeletios A Dimopoulos

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.